Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M115,898Revenue (TTM) $M22,156Net Margin (%)32.6Altman Z-Score2.6
Enterprise Value $M115,465EPS (TTM) $9.5Operating Margin %39.9Piotroski F-Score7
P/E(ttm)16.3Beneish M-Score-2.5Pre-tax Margin (%)37.7Higher ROA y-yY
Price/Book4.010-y EBITDA Growth Rate %11.6Quick Ratio4.7Cash flow > EarningsY
Price/Sales5.35-y EBITDA Growth Rate %15.8Current Ratio5.0Lower Leverage y-yN
Price/Free Cash Flow13.4y-y EBITDA Growth Rate %23.9ROA % (ttm)10.1Higher Current Ratio y-yN
Dividend Yield %2.3PEG1.0ROE % (ttm)26.0Less Shares Outstanding y-yY
Payout Ratio %36.0Shares Outstanding M751ROIC % (ttm)26.5Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNFirst Eagle Investment 2016-03-31 Add0.11%$140.9 - $162.33
($148.76)
$ 154.284%Add 28.98%1,235,154
AMGNJoel Greenblatt 2016-03-31 Add0.08%$140.9 - $162.33
($148.76)
$ 154.284%Add 16.86%323,405
AMGNVanguard Health Care Fund 2016-03-31 Reduce-0.05%$140.9 - $162.33
($148.76)
$ 154.284%Reduce -2.91%5,241,755
AMGNGeorge Soros 2016-03-31 Sold Out -0.01%$140.9 - $162.33
($148.76)
$ 154.284%Sold Out0
AMGNKen Fisher 2016-03-31 Reduce-0.01%$140.9 - $162.33
($148.76)
$ 154.284%Reduce -17.38%112,693
AMGNDodge & Cox 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 154.284%Reduce -6.62%43,557
AMGNMario Gabelli 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 154.284%Reduce -5.02%37,210
AMGNRuane Cunniff 2016-03-31 Sold Out $140.9 - $162.33
($148.76)
$ 154.284%Sold Out0
AMGNJoel Greenblatt 2015-12-31 Reduce-0.18%$141.22 - $164.58
($157.65)
$ 154.28-2%Reduce -31.85%276,751
AMGNFirst Eagle Investment 2015-12-31 Add0.17%$141.22 - $164.58
($157.65)
$ 154.28-2%Add 73.61%957,656
AMGNVanguard Health Care Fund 2015-12-31 Reduce-0.05%$141.22 - $164.58
($157.65)
$ 154.28-2%Reduce -3.25%5,398,985
AMGNGeorge Soros 2015-12-31 Add0.01%$141.22 - $164.58
($157.65)
$ 154.28-2%Add 109.52%4,400
AMGNDodge & Cox 2015-12-31 Reduce$141.22 - $164.58
($157.65)
$ 154.28-2%Reduce -3.52%46,644
AMGNMario Gabelli 2015-12-31 Reduce$141.22 - $164.58
($157.65)
$ 154.28-2%Reduce -3.39%39,175
AMGNKen Fisher 2015-12-31 Add$141.22 - $164.58
($157.46)
$ 154.28-2%Add 2.07%136,400
AMGNJoel Greenblatt 2015-09-30 Reduce-0.07%$132.24 - $176.59
($157.63)
$ 154.28-2%Reduce -11.55%406,106
AMGNFirst Eagle Investment 2015-09-30 Add0.04%$132.24 - $176.59
($157.63)
$ 154.28-2%Add 22.77%551,600
AMGNKen Fisher 2015-09-30 Reduce-0.01%$132.24 - $176.59
($157.63)
$ 154.28-2%Reduce -13.84%133,632
AMGNDodge & Cox 2015-09-30 Reduce$132.24 - $176.59
($157.63)
$ 154.28-2%Reduce -4.84%48,344
AMGNGeorge Soros 2015-09-30 Buy $132.24 - $176.59
($157.63)
$ 154.28-2%New holding2,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.120.1view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.99-2.35view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.21-1.86view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.485.32view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.840.29view
Hassan FredDirector 2015-08-19Buy3,010$166.63-7.41view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-14.48view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-1.77view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.87-2.27view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-8.88view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
    John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Citigroup, Amgen Are Trading With Wide Margin of Safety Mar 30 2016 
    Amgen: Should I Just Sit and Wait? Mar 18 2016 
    Gilead, Johnson & Johnson or Roche? Feb 11 2016 
    Plenty of Opportunity to Buy Individual Stocks: John Buckingham Feb 02 2016 
    Alan Fournier Sells GM, Buys Molson Coors Brewing Jan 03 2016 

    More From Other Websites
    3 Potential Stock-Moving Drug Events In The Second Half Of 2016 Jul 01 2016
    AstraZeneca Transfers Valeant's European Rights To Troubled Drug Jul 01 2016
    Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here Jul 01 2016
    What Is Xencor’s XmAb Technology? Jun 30 2016
    Three Biotech Giants…But Only Two are Worth Buying Jun 29 2016
    Top 6 Research Reports for June 29, 2016 Jun 29 2016
    Behind the Recent Fall in BioMarin’s Premium Valuation Jun 29 2016
    Coverage initiated on Amgen by Bernstein Jun 29 2016
    5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero Jun 28 2016
    Biotechs: After Brexit, Buy the Stocks and Get the Pipelines For Free Jun 28 2016
    The Largest Drug Pipelines Will Surprise You Jun 27 2016
    Alexion Pharmaceuticals: Brexit Be Damned; Citigroup Ups to Buy Citing "Dark Sky Valuation" Jun 27 2016
    Is Brexit Good for Biotech? Maybe Jun 27 2016
    Short Sellers Run for Cover From Major Biotechs Jun 27 2016
    Biotech: Buy the Brexit Blowup? Jun 24 2016
    Amgen Fits Into Pfizer's Restructuring Plans Perfectly Jun 24 2016
    Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization... Jun 24 2016
    Why Biotechnology Goliath Amgen Is a Solid Long-Term Investment Jun 23 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)